206 related articles for article (PubMed ID: 31484660)
21. Celecoxib for the prevention of colorectal adenomatous polyps.
Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
[TBL] [Abstract][Full Text] [Related]
22. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
Ishikawa H; Mutoh M; Sato Y; Doyama H; Tajika M; Tanaka S; Horimatsu T; Takeuchi Y; Kashida H; Tashiro J; Ezoe Y; Nakajima T; Ikematsu H; Hori S; Suzuki S; Otani T; Takayama T; Ohda Y; Mure K; Wakabayashi K; Sakai T
Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):474-481. PubMed ID: 33812492
[TBL] [Abstract][Full Text] [Related]
23. DFMO: targeted risk reduction therapy for colorectal neoplasia.
Laukaitis CM; Gerner EW
Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):495-506. PubMed ID: 22122766
[TBL] [Abstract][Full Text] [Related]
24. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
Sandler RS; Halabi S; Baron JA; Budinger S; Paskett E; Keresztes R; Petrelli N; Pipas JM; Karp DD; Loprinzi CL; Steinbach G; Schilsky R
N Engl J Med; 2003 Mar; 348(10):883-90. PubMed ID: 12621132
[TBL] [Abstract][Full Text] [Related]
25. Rectal aberrant crypt foci (ACF) as a predictor of benign and malignant neoplastic lesions in the large intestine.
Kowalczyk M; Orłowski M; Klepacki Ł; Zinkiewicz K; Kurpiewski W; Kaczerska D; Pesta W; Zieliński E; Siermontowski P
BMC Cancer; 2020 Feb; 20(1):133. PubMed ID: 32075595
[TBL] [Abstract][Full Text] [Related]
26. Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention.
Meyskens FL; Gerner EW; Emerson S; Pelot D; Durbin T; Doyle K; Lagerberg W
J Natl Cancer Inst; 1998 Aug; 90(16):1212-8. PubMed ID: 9719082
[TBL] [Abstract][Full Text] [Related]
27. Predictive value of rectal aberrant crypt foci for intraepithelial neoplasia in ulcerative colitis - a cross-sectional study.
Freire P; Figueiredo P; Cardoso R; Manuel Donato M; Ferreira M; Mendes S; Silva MR; Cipriano MA; Ferreira AM; Vasconcelos H; Portela F; Sofia C
Scand J Gastroenterol; 2014 Oct; 49(10):1219-29. PubMed ID: 25157637
[TBL] [Abstract][Full Text] [Related]
28. A randomized trial of aspirin to prevent colorectal adenomas.
Baron JA; Cole BF; Sandler RS; Haile RW; Ahnen D; Bresalier R; McKeown-Eyssen G; Summers RW; Rothstein R; Burke CA; Snover DC; Church TR; Allen JI; Beach M; Beck GJ; Bond JH; Byers T; Greenberg ER; Mandel JS; Marcon N; Mott LA; Pearson L; Saibil F; van Stolk RU
N Engl J Med; 2003 Mar; 348(10):891-9. PubMed ID: 12621133
[TBL] [Abstract][Full Text] [Related]
29. Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas.
Raj KP; Zell JA; Rock CL; McLaren CE; Zoumas-Morse C; Gerner EW; Meyskens FL
Br J Cancer; 2013 Feb; 108(3):512-8. PubMed ID: 23340449
[TBL] [Abstract][Full Text] [Related]
30. Prevention of colon cancer and modulation of aberrant crypt foci, cell proliferation, and apoptosis by retinoids and NSAIDs.
Pereira MA
Adv Exp Med Biol; 1999; 470():55-63. PubMed ID: 10709674
[TBL] [Abstract][Full Text] [Related]
31. An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis.
Lynch PM; Burke CA; Phillips R; Morris JS; Slack R; Wang X; Liu J; Patterson S; Sinicrope FA; Rodriguez-Bigas MA; Half E; Bulow S; Latchford A; Clark S; Ross WA; Malone B; Hasson H; Richmond E; Hawk E
Gut; 2016 Feb; 65(2):286-95. PubMed ID: 25792707
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
33. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial.
Cole BF; Baron JA; Sandler RS; Haile RW; Ahnen DJ; Bresalier RS; McKeown-Eyssen G; Summers RW; Rothstein RI; Burke CA; Snover DC; Church TR; Allen JI; Robertson DJ; Beck GJ; Bond JH; Byers T; Mandel JS; Mott LA; Pearson LH; Barry EL; Rees JR; Marcon N; Saibil F; Ueland PM; Greenberg ER;
JAMA; 2007 Jun; 297(21):2351-9. PubMed ID: 17551129
[TBL] [Abstract][Full Text] [Related]
34. Interaction of calcium supplementation and nonsteroidal anti-inflammatory drugs and the risk of colorectal adenomas.
Grau MV; Baron JA; Barry EL; Sandler RS; Haile RW; Mandel JS; Cole BF
Cancer Epidemiol Biomarkers Prev; 2005 Oct; 14(10):2353-8. PubMed ID: 16214916
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans.
Rudolph RE; Dominitz JA; Lampe JW; Levy L; Qu P; Li SS; Lampe PD; Bronner MP; Potter JD
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):605-8. PubMed ID: 15767337
[TBL] [Abstract][Full Text] [Related]
36. Rectal aberrant crypt foci identified using high-magnification-chromoscopic colonoscopy: biomarkers for flat and depressed neoplasia.
Hurlstone DP; Karajeh M; Sanders DS; Drew SK; Cross SS
Am J Gastroenterol; 2005 Jun; 100(6):1283-9. PubMed ID: 15929758
[TBL] [Abstract][Full Text] [Related]
37. Effect of Low-dose and Standard-dose Aspirin on PGE
Drew DA; Schuck MM; Magicheva-Gupta MV; Stewart KO; Gilpin KK; Miller P; Parziale MP; Pond EN; Takacsi-Nagy O; Zerjav DC; Chin SM; Mackinnon Krems J; Meixell D; Joshi AD; Ma W; Colizzo FP; Carolan PJ; Nishioka NS; Staller K; Richter JM; Khalili H; Gala MK; Garber JJ; Chung DC; Yarze JC; Zukerberg L; Petrucci G; Rocca B; Patrono C; Milne GL; Wang M; Chan AT
Cancer Prev Res (Phila); 2020 Oct; 13(10):877-888. PubMed ID: 32718943
[TBL] [Abstract][Full Text] [Related]
38. Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas.
Huls G; Koornstra JJ; Kleibeuker JH
Lancet; 2003 Jul; 362(9379):230-2. PubMed ID: 12885487
[TBL] [Abstract][Full Text] [Related]
39. Aspirin and folic acid for the prevention of recurrent colorectal adenomas.
Logan RF; Grainge MJ; Shepherd VC; Armitage NC; Muir KR;
Gastroenterology; 2008 Jan; 134(1):29-38. PubMed ID: 18022173
[TBL] [Abstract][Full Text] [Related]
40. Dysplastic Aberrant Crypt Foci: Biomarkers of Early Colorectal Neoplasia and Response to Preventive Intervention.
Clapper ML; Chang WL; Cooper HS
Cancer Prev Res (Phila); 2020 Mar; 13(3):229-240. PubMed ID: 32132117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
